Jul 31, 2023 / NTS GMT
Operator
Good afternoon, everyone. Our clock has now ticked pass midday. So we'll get started with today's quarterly investor briefing with Pharmaxis CEO, Gary Phillips, who also has some updates from the FDA. My name is Alfred, I'm part of Pharmaxis Investor Relations team, I will assist in running call. (Operator Instructions)
It's obviously a very busy day on the AXS explained the last day of month. And there's plenty of information for investors to dissect, including these new FDA developments with Pharmaxis. So Gary, I won't take up anymore of your time. Let me hand over to you.
Gary Phillips - Pharmaxis Ltd - CEO
Thanks, Alfred, and good afternoon, everybody. I presented a couple of investor meetings in the last few weeks and today is a good chance to pull some of the threads that have been going on together and draw some conclusions about where we are as a company right now. Because obviously, we released lot of data in the last couple of months. I'm just going to go through the highlights of what we've announced. And then as Alfred say, I'm very happy to
Q4 2023 Pharmaxis Ltd Activities Report Call Transcript
Jul 31, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers